SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 20, 2005. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific internal transaction rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs.
Management Commentary and Risks
Administrators of the Plan notified GlaxoSmithKline plc and Dr. R. Greig on December 20, 2005, of an increase in the notional allocation of Ordinary Share ADRs. This transaction occurred on December 16, 2005, at a price of $51.61 per share. The notification complies with Disclosure Rule 3.1.4R(1)(a). No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Checklist
- Verify the specific terms of the US Retirement Savings Plan regarding notional ADR allocations.
- Confirm the identity and role of Dr. R. Greig within the company's governance structure.
- Check the market price of GSK Ordinary Share ADRs on December 16, 2005, to validate the $51.61 transaction price.
- Review subsequent filings for broader financial performance data, as this 6-K contains no financial statements.